Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment.

Rossenkhan R, Rolland M, Labuschagne JPL, Ferreira RC, Magaret CA, Carpp LN, Matsen Iv FA, Huang Y, Rudnicki EE, Zhang Y, Ndabambi N, Logan M, Holzman T, Abrahams MR, Anthony C, Tovanabutra S, Warth C, Botha G, Matten D, Nitayaphan S, Kibuuka H, Sawe FK, Chopera D, Eller LA, Travers S, Robb ML, Williamson C, Gilbert PB, Edlefsen PT.

Viruses. 2019 Jul 3;11(7). pii: E607. doi: 10.3390/v11070607.

2.

Expansion of Stem Cell-Like CD4+ Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression.

Pušnik J, Eller MA, Tassaneetrithep B, Schultz BT, Eller LA, Nitayaphan S, Kosgei J, Maganga L, Kibuuka H, Alter G, Michael NL, Robb ML, Streeck H.

J Virol. 2019 Jun 28;93(14). pii: e00377-19. doi: 10.1128/JVI.00377-19. Print 2019 Jul 15.

PMID:
31043532
3.

HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study.

Kiweewa F, Esber A, Musingye E, Reed D, Crowell TA, Cham F, Semwogerere M, Namagembe R, Nambuya A, Kafeero C, Tindikahwa A, Eller LA, Millard M, Gelderblom HC, Keshinro B, Adamu Y, Maswai J, Owuoth J, Sing'oei VC, Maganga L, Bahemana E, Khamadi S, Robb ML, Ake JA, Polyak CS, Kibuuka H.

PLoS One. 2019 Feb 5;14(2):e0211344. doi: 10.1371/journal.pone.0211344. eCollection 2019.

4.

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H.

Lancet. 2018 Jul 21;392(10143):232-243. doi: 10.1016/S0140-6736(18)31364-3. Epub 2018 Jul 6.

5.

Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.

Ake JA, Schuetz A, Pegu P, Wieczorek L, Eller MA, Kibuuka H, Sawe F, Maboko L, Polonis V, Karasavva N, Weiner D, Sekiziyivu A, Kosgei J, Missanga M, Kroidl A, Mann P, Ratto-Kim S, Anne Eller L, Earl P, Moss B, Dorsey-Spitz J, Milazzo M, Laissa Ouedraogo G, Rizvi F, Yan J, Khan AS, Peel S, Sardesai NY, Michael NL, Ngauy V, Marovich M, Robb ML.

J Infect Dis. 2017 Nov 27;216(9):1080-1090. doi: 10.1093/infdis/jix456.

6.

Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection.

Kijak GH, Sanders-Buell E, Chenine AL, Eller MA, Goonetilleke N, Thomas R, Leviyang S, Harbolick EA, Bose M, Pham P, Oropeza C, Poltavee K, O'Sullivan AM, Billings E, Merbah M, Costanzo MC, Warren JA, Slike B, Li H, Peachman KK, Fischer W, Gao F, Cicala C, Arthos J, Eller LA, O'Connell RJ, Sinei S, Maganga L, Kibuuka H, Nitayaphan S, Rao M, Marovich MA, Krebs SJ, Rolland M, Korber BT, Shaw GM, Michael NL, Robb ML, Tovanabutra S, Kim JH.

PLoS Pathog. 2017 Sep 14;13(9):e1006620. doi: 10.1371/journal.ppat.1006620. eCollection 2017 Sep.

7.

Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection.

Kijak GH, Sanders-Buell E, Chenine AL, Eller MA, Goonetilleke N, Thomas R, Leviyang S, Harbolick EA, Bose M, Pham P, Oropeza C, Poltavee K, O'Sullivan AM, Billings E, Merbah M, Costanzo MC, Warren JA, Slike B, Li H, Peachman KK, Fischer W, Gao F, Cicala C, Arthos J, Eller LA, O'Connell RJ, Sinei S, Maganga L, Kibuuka H, Nitayaphan S, Rao M, Marovich MA, Krebs SJ, Rolland M, Korber BT, Shaw GM, Michael NL, Robb ML, Tovanabutra S, Kim JH.

PLoS Pathog. 2017 Jul 31;13(7):e1006510. doi: 10.1371/journal.ppat.1006510. eCollection 2017 Jul. Erratum in: PLoS Pathog. 2017 Sep 14;13(9):e1006620.

8.

Epidemiology and Surveillance of Influenza Viruses in Uganda between 2008 and 2014.

Wabwire-Mangen F, Mimbe DE, Erima B, Mworozi EA, Millard M, Kibuuka H, Lukwago L, Bwogi J, Kiconco J, Tugume T, Mulei S, Ikomera C, Tsui S, Malinzi S, Kasasa S, Coldren R, Byarugaba DK.

PLoS One. 2016 Oct 18;11(10):e0164861. doi: 10.1371/journal.pone.0164861. eCollection 2016.

9.

Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection.

Demers KR, Makedonas G, Buggert M, Eller MA, Ratcliffe SJ, Goonetilleke N, Li CK, Eller LA, Rono K, Maganga L, Nitayaphan S, Kibuuka H, Routy JP, Slifka MK, Haynes BF, McMichael AJ, Bernard NF, Robb ML, Betts MR.

PLoS Pathog. 2016 Aug 3;12(8):e1005805. doi: 10.1371/journal.ppat.1005805. eCollection 2016 Aug.

10.

Whole-genome analysis of influenza A(H1N1)pdm09 viruses isolated in Uganda from 2009 to 2011.

Byarugaba DK, Erima B, Millard M, Kibuuka H, Lkwago L, Bwogi J, Mimbe D, Kiconco JB, Tugume T, Mworozi EA, Turner J, Mckenzie PP, Webby RR, Webster RG, Foret C, Ducatez MF, Coldren R, Wabwire-Mangen F, Krauss S.

Influenza Other Respir Viruses. 2016 Nov;10(6):486-492. doi: 10.1111/irv.12401. Epub 2016 Jul 19.

11.

Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand.

Robb ML, Eller LA, Kibuuka H, Rono K, Maganga L, Nitayaphan S, Kroon E, Sawe FK, Sinei S, Sriplienchan S, Jagodzinski LL, Malia J, Manak M, de Souza MS, Tovanabutra S, Sanders-Buell E, Rolland M, Dorsey-Spitz J, Eller MA, Milazzo M, Li Q, Lewandowski A, Wu H, Swann E, O'Connell RJ, Peel S, Dawson P, Kim JH, Michael NL; RV 217 Study Team.

N Engl J Med. 2016 Jun 2;374(22):2120-30. doi: 10.1056/NEJMoa1508952. Epub 2016 May 18.

12.

Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection.

Eller MA, Goonetilleke N, Tassaneetrithep B, Eller LA, Costanzo MC, Johnson S, Betts MR, Krebs SJ, Slike BM, Nitayaphan S, Rono K, Tovanabutra S, Maganga L, Kibuuka H, Jagodzinski L, Peel S, Rolland M, Marovich MA, Kim JH, Michael NL, Robb ML, Streeck H.

J Virol. 2016 Mar 28;90(8):4005-4016. doi: 10.1128/JVI.02785-15. Print 2016 Apr.

13.

Sex and Urbanicity Contribute to Variation in Lymphocyte Distribution across Ugandan Populations.

Naluyima P, Eller LA, Ouma BJ, Kyabaggu D, Kataaha P, Guwatudde D, Kibuuka H, Wabwire-Mangen F, Robb ML, Michael NL, de Souza MS, Sandberg JK, Eller MA.

PLoS One. 2016 Jan 5;11(1):e0146196. doi: 10.1371/journal.pone.0146196. eCollection 2016.

14.

Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study.

Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, Eller MA, Eller LA, Michael NL, Honko AN, Olinger GG Jr, Schoepp RJ, Hepburn MJ, Hensley LE, Robb ML.

Lancet Infect Dis. 2015 Aug;15(8):905-12. doi: 10.1016/S1473-3099(15)70152-0. Epub 2015 Apr 21.

PMID:
25910637
15.

How much does it cost to improve access to voluntary medical male circumcision among high-risk, low-income communities in Uganda?

Larson B, Tindikahwa A, Mwidu G, Kibuuka H, Magala F.

PLoS One. 2015 Mar 16;10(3):e0119484. doi: 10.1371/journal.pone.0119484. eCollection 2015.

16.

Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.

Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, Sitar S, Glover D, Hu Z, Joshi G, Stanley D, Kunchai M, Eller LA, Bailer RT, Koup RA, Nabel GJ, Mascola JR, Sullivan NJ, Graham BS, Roederer M, Michael NL, Robb ML, Ledgerwood JE; RV 247 Study Team.

Lancet. 2015 Apr 18;385(9977):1545-54. doi: 10.1016/S0140-6736(14)62385-0. Epub 2014 Dec 23.

PMID:
25540891
17.

Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals.

Hu H, Eller MA, Zafar S, Zhou Y, Gu M, Wei Z, Currier JR, Marovich MA, Kibuuka HN, Bailer RT, Koup RA, Robb ML, Michael NL, Kim JH, Ratto-Kim S.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13439-44. doi: 10.1073/pnas.1400446111. Epub 2014 Sep 2.

18.
19.

Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.

Crawford KW, Wakabi S, Kibuuka H, Magala F, Keshinro B, Okoye I, Akintunde E, Hamm TE.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):796-9. doi: 10.1089/AID.2013.0294. Epub 2014 Jun 6.

PMID:
24798614
20.

Prevalence of influenza A viruses in livestock and free-living waterfowl in Uganda.

Kirunda H, Erima B, Tumushabe A, Kiconco J, Tugume T, Mulei S, Mimbe D, Mworozi E, Bwogi J, Luswa L, Kibuuka H, Millard M, Byaruhanga A, Ducatez MF, Krauss S, Webby RJ, Webster RG, Wurapa K, Byarugaba DK, Wabwire-Mangen F.

BMC Vet Res. 2014 Feb 27;10:50. doi: 10.1186/1746-6148-10-50.

21.

Genetic analysis of influenza B viruses isolated in Uganda during the 2009-2010 seasons.

Byarugaba DK, Erima B, Millard M, Kibuuka H, L L, Bwogi J, Mimbe D, Mworozi EA, Sharp B, Krauss S, Webby RJ, Webster RG, Martin SK, Wabwire-Mangen F, Ducatez MF.

Virol J. 2013 Jan 5;10:11. doi: 10.1186/1743-422X-10-11.

22.

Short communication: Colony-forming hematopoietic progenitor cells are not preferentially infected by HIV type 1 subtypes A and D in vivo.

Mullis CE, Oliver AE, Eller LA, Guwatudde D, Mueller AC, Eller MA, Kibuuka H, Robb M, Quinn TC, Redd AD.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1119-23. doi: 10.1089/AID.2011.0179. Epub 2012 Feb 2.

23.

Molecular epidemiology of influenza A/H3N2 viruses circulating in Uganda.

Byarugaba DK, Ducatez MF, Erima B, Mworozi EA, Millard M, Kibuuka H, Lukwago L, Bwogi J, Kaira BB, Mimbe D, Schnabel DC, Krauss S, Darnell D, Webby RJ, Webster RG, Wabwire-Mangen F.

PLoS One. 2011;6(11):e27803. doi: 10.1371/journal.pone.0027803. Epub 2011 Nov 21.

24.

B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.

Oballah P, Flach B, Eller LA, Eller MA, Ouma B, de Souza M, Kibuuka HN, Wabwire-Mangen F, Brown BK, Michael NL, Robb ML, Montefiori D, Polonis VR.

PLoS One. 2011;6(8):e22653. doi: 10.1371/journal.pone.0022653. Epub 2011 Aug 23.

25.

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.

Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P, Sinangil F, de Bruyn G, Gray GE, Roux S, Bekker LG, Dilraj A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amornkul PN, Gilmour J, Hural J, Buchbinder SP, Seaman MS, Dolin R, Baden LR, Carville A, Mansfield KG, Pau MG, Goudsmit J.

Vaccine. 2011 Jul 18;29(32):5203-9. doi: 10.1016/j.vaccine.2011.05.025. Epub 2011 May 25.

26.

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, Shaffer D, Eller LA, Kibaya R, Eller MA, Schindler KB, Schuetz A, Millard M, Kroll J, Dally L, Hoelscher M, Bailer R, Cox JH, Marovich M, Birx DL, Graham BS, Michael NL, de Souza MS, Robb ML.

J Infect Dis. 2010 Feb 15;201(4):600-7. doi: 10.1086/650299.

27.

Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I/II trial in East Africa.

Kibuuka H, Guwatudde D, Kimutai R, Maganga L, Maboko L, Watyema C, Sawe F, Shaffer D, Matsiko D, Millard M, Michael N, Wabwire-Mangen F, Robb M.

PLoS One. 2009;4(4):e5164. doi: 10.1371/journal.pone.0005164. Epub 2009 Apr 10.

28.

HLA class I allele and haplotype diversity in Ugandans supports the presence of a major east African genetic cluster.

Kijak GH, Walsh AM, Koehler RN, Moqueet N, Eller LA, Eller M, Currier JR, Wang Z, Wabwire-Mangen F, Kibuuka HN, Michael NL, Robb ML, McCutchan FE.

Tissue Antigens. 2009 Mar;73(3):262-9. doi: 10.1111/j.1399-0039.2008.01192.x.

PMID:
19254258
29.

Relatively low HIV infection rates in rural Uganda, but with high potential for a rise: a cohort study in Kayunga District, Uganda.

Guwatudde D, Wabwire-Mangen F, Eller LA, Eller M, McCutchan F, Kibuuka H, Millard M, Sewankambo N, Serwadda D, Michael N, Robb M; Kayunga Cohort Research Team.

PLoS One. 2009;4(1):e4145. doi: 10.1371/journal.pone.0004145. Epub 2009 Jan 7.

30.

Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials.

Eller LA, Eller MA, Ouma B, Kataaha P, Kyabaggu D, Tumusiime R, Wandege J, Sanya R, Sateren WB, Wabwire-Mangen F, Kibuuka H, Robb ML, Michael NL, de Souza MS.

PLoS One. 2008;3(12):e3919. doi: 10.1371/journal.pone.0003919. Epub 2008 Dec 11.

31.

Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans.

Eller MA, Eller LA, Opollo MS, Ouma BJ, Oballah PO, Galley L, Karnasuta C, Kim SR, Robb ML, Michael NL, Kibuuka H, Wabwire-Mangen F, Graham BS, Birx DL, de Souza MS, Cox JH.

Vaccine. 2007 Nov 7;25(45):7737-42. Epub 2007 Sep 17.

PMID:
17920731
32.

Large-scale human immunodeficiency virus rapid test evaluation in a low-prevalence ugandan blood bank population.

Eller LA, Eller MA, Ouma BJ, Kataaha P, Bagaya BS, Olemukan RL, Erima S, Kawala L, de Souza MS, Kibuuka H, Wabwire-Mangen F, Peel SA, O'Connell RJ, Robb ML, Michael NL.

J Clin Microbiol. 2007 Oct;45(10):3281-5. Epub 2007 Aug 15.

Supplemental Content

Loading ...
Support Center